Daiichi Sankyo Business Model Canvas

CMOs and CDMOs enable Daiichi Sankyo to scale biologics, sterile fill-finish and specialized production, complementing in-house sites; the global CDMO market was about $60 billion in 2024, underscoring available capacity. Flexible external capacity mitigates supply risk and accelerates global launches, with tech transfers and regular GMP audits ensuring quality. The network smooths volatility, supporting rapid ramp-up for peak demand.

Academic and biotech alliances accelerate oncology and CVR discovery, de-risk early R&D and fill pipeline gaps.

CDMOs/CROs scale manufacturing and trials; CRO market ~$65B (2024), CDMO ~$60B (2024), RWE ~$4.2B (2024).

Regulatory, HTA, distribution and patient-group partners secure approvals, reimbursement and global access.

Scale reliable GMP production for small molecules, biologics, and ADCs across Daiichi Sankyo’s Japan, US and EU manufacturing network, with tech transfer programs to enable efficient global supply. Implement robust quality systems, validation and continuous improvement to meet regulatory standards and reduce batch deviations. Secure raw materials and dual-source critical components to maintain supply continuity and minimize disruption.

Discovery and development focus on oncology and CV‑renal with biomarker‑guided trials and cross‑functional, adaptive Ph1–Ph3 execution. Global regulatory strategy uses FDA standard review (10 months) and EMA centralized procedure (210 days) with HEOR 1–5 year budget models. Manufacturing spans Japan, US and EU with GMP for small molecules, biologics and ADCs; launches and lifecycle management (Enhertu label expansions through 2024) drive commercialization.

Facilities for API, biologics and specialized modalities—operating over 15 manufacturing and R&D sites globally as of 2024—give Daiichi Sankyo direct control over production. Robust quality systems meet GMP and global regulatory standards, ensuring reliability. Integrated supply chain capabilities secure raw materials and distribution across markets. Scalable capacity supports rising global demand for Enhertu and other specialty assets.

Experienced R&D and regulatory teams supported by ~16,000 employees (2024) and proprietary IP/ADC know‑how drive innovation. Integrated real‑world and biomarker data inform trials and reimbursement. 15+ manufacturing/R&D sites and 30+ country affiliates ensure supply and commercialization; partnerships (eg Enhertu co‑dev with AstraZeneca; approvals US/EU/JP 2024) expand reach.

Daiichi Sankyo leverages strong manufacturing and QA across over 20 countries and a global workforce of about 16,000 (2024) to maintain consistent product availability. Redundant regional sourcing and multiple production sites reduce shortage risk and support continuity. Robust cold-chain logistics and validated distribution networks protect product integrity so providers and patients can trust ongoing care.

Daiichi Sankyo delivers first‑/best‑in‑class oncology and CV‑renal medicines (Enhertu in 20+ countries by 2024), precision ADCs and companion diagnostics improving efficacy/safety, HEOR showing 22% fewer hospitalizations and ~$2,500 avoided cost/patient‑yr, and global manufacturing with ~16,000 workforce plus patient support to boost adherence.

Enrollment assistance and copay support reduce access barriers, with a 2024 IQVIA analysis showing patient support programs can lower treatment abandonment and improve initiation rates by about 11%.

Adherence tools and tailored education delivered via apps and nurse coaching raise persistence and clinical outcomes, correlating with reported adherence gains in real-world 2024 studies.

Pharmacovigilance systems ensure proactive safety follow-up and case reporting, supporting regulatory compliance and risk mitigation in 2024 post-marketing surveillance frameworks.

Closed-loop feedback from patient surveys and claims data in 2024 drives iterative service improvements and targets resource allocation to higher-impact interventions.

Scientific exchange (peer-reviewed data, MSLs; ASCO 2024 attendance ≈42,000) builds trust; KOLs and guideline alignment drive adoption. Key account teams, contracting and patient access programs enhance formulary inclusion and retention. Digital omnichannel plus adherence support lifted virtual HCP interactions +30% and reduced treatment abandonment ~11% in 2024.

HCP portals provide 24/7 access to materials, samples and ordering workflows, supporting field teams and compliant digital rep interactions in 2024. Virtual education scales scientific updates across global HCP cohorts via on-demand modules and live webinars. Patient sites enable support program enrollment and adherence tools, while embedded analytics track engagement, prescribing signals and unmet needs in real time.

Specialty-focused field teams, HUB services and HCP portals drive uptake for complex Daiichi Sankyo therapies, matching high-touch support to hospital and infusion channels. Global wholesalers, cold-chain logistics and tender participation sustain supply across 20+ countries. Companion diagnostics (40+ FDA-cleared in 2024) speed initiation and improve appropriate prescribing.

Hospital formulary and P&T committees drive inclusion and clinical pathways, prioritizing total cost of care and operational efficiency; they demand reliable supply, flexible contracting and outcomes data for decisions. By 2024, value‑based contracts remained under 5% of US drug spend, so real‑world outcomes evidence is critical for uptake.

Oncologists/cancer centers drive ADC uptake; by 2024 >10 ADCs approved, requiring long‑term safety, RWE and access programs. Cardiologists/nephrologists prioritize survival/HF benefit (SGLT2 RRR ~30–44%) and cost‑effectiveness (~100,000 USD/QALY). Payers/P&T demand RCTs plus budget‑impact/CEA; value‑based contracts <5% of US drug spend (2024).

Sales force, medical affairs and omnichannel investments drive scale-heavy cost bases; industry data show commercial spend averaged about 24% of revenue in 2023–24 (IQVIA), underlining Daiichi Sankyo's need for large-scale teams. HEOR, pricing and tendering incur specialized staffing and consultancy fees, while patient support programs can represent single-digit to low-double-digit percent shares of launch budgets. Launches concentrate expenditures upfront, often front-loading 50–70% of first‑year commercial investment.

R&D and clinical trials dominate costs—JPY 189.7 billion R&D in FY2023 (ended Mar 2024)—with CROs, site fees and biomarker testing as primary drivers. Manufacturing/COGS higher for biologics/ADCs (30–40% revenue; ADCs 2–3x unit COGS), plus 10–15% premium for redundant supply chains. Commercial spend (~24% revenue in 2023–24) and global compliance, PV, legal/IP add recurring overhead; partnerships bring upfronts/milestones and royalties.

Royalties from licensed assets and technologies provide recurring income for Daiichi Sankyo, underpinning collaboration revenue reported in 2024. Out-licensing non-core programs monetizes R&D spend and accelerates partner-driven development. Platform licensing extends reach into new markets and therapeutic areas, and the resulting predictable cash flows support reinvestment into priority pipelines.

Prescription drug sales remain core for Daiichi Sankyo, with FY2024 consolidated pharma sales of ¥1,062.5 billion driven by oncology and CV-renal portfolios. Milestones, collaboration income and royalties provided recurring upside in 2024, often disclosed as material but not fully itemized. Companion diagnostics, testing and institutional tenders support adoption and volume-based, predictable revenue streams.